Page last updated: 2024-12-06

tetramethylenedisulfotetramine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

tetramethylenedisulfotetramine: induces convulsions; inhibitor of GABA; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID64148
SCHEMBL ID1059003
MeSH IDM0055766

Synonyms (32)

Synonym
tetramethylenedisulfotetramine
tetramine (adamantane derivative)
2,3,5,7-tetrazatricyclo[3.3.1.1(sup 3,7)]decane-2,2,6,6-tetroxide
wln: t66 b6 a b- c 1b i aswn dnswn hntj
tets
nsc-172824
2,3,5,7-tetraazaadamantane, 2,2,6,6-tetraoxide
tetramethylenedisulphotetramine
nsc172824
2,3,5,7-tetraazatricyclo[3.3.1.13,7]decane, 2,2,6,6-tetraoxide
2,3,5,7-tetraazaadamantane, 2,2,4,4-tetraoxide
80-12-6
2,6-dithia-1,3,5,7-tetrazatricyclo(3.3.1.1(sup 3,7))decane-2,2,6,6-tetraoxide
2,6-dithia-1,3,5,7-tetraazatricyclo(3.3.1.13,7)decane, 2,2,6,6-tetraoxide
2,6-dithia-1,3,5,7-tetraazaadamantane, 2,2,6,6-tetraoxide
2,4-dithia-1,3,5,7-tetraazaadamantane, 2,2,4,4-tetraoxide
brn 0257816
dsta
nsc 172824
f6ts3wme05 ,
4-27-00-09647 (beilstein handbook reference)
unii-f6ts3wme05
SCHEMBL1059003
2,6-dithia-1,3,5,7-tetraazatricyclo[3.3.1.13,7]decane, 2,2,6,6-tetraoxide
tetramethylenedisulfotetramine [mi]
DTXSID8040307
AGGKEGLBGGJEBZ-UHFFFAOYSA-N
tetramethylenedisulfotetramide
199488-98-7
Q7706590
tetramethylenedisulfotetramine 100 microg/ml in dichloromethane
2lambda6,6lambda6-dithia-1,3,5,7-tetrazatricyclo[3.3.1.13,7]decane 2,2,6,6-tetraoxide

Research Excerpts

Overview

Tetramethylenedisulfotetramine is a potent convulsant poison that is thought to trigger seizures by inhibiting the function of the type A gamma-aminobutyric acid receptor (GABAAR) There is currently no approved antidote for this poison.

ExcerptReferenceRelevance
"Tetramethylenedisulfotetramine (TMDT) is a synthetic neurotoxic rodenticide considered a chemical threat agent. "( Developmental and sex differences in tetramethylenedisulfotetramine (TMDT)-induced syndrome in rats.
Lauková, M; Shakarjian, MP; Velíšek, L; Velíšková, J, 2018
)
2.2
"Tetramethylenedisulfotetramine (TMDT) is a synthetic neurotoxic rodenticide and potential chemical threat agent. "( Mouse model of human poisonings with tetramethylenedisulfotetramine: Characterization of the effect of exposure route on syndrome outcomes.
Lauková, M; Pervez, S; Rosman, R; Shakarjian, MP; Velíšek, L; Velíšková, J, 2019
)
2.23
"Tetramethylenedisulfotetramine (TETS) is a potent convulsant poison that is thought to trigger seizures by inhibiting the function of the type A gamma-aminobutyric acid receptor (GABAAR). "( Behavioral assessment of NIH Swiss mice acutely intoxicated with tetramethylenedisulfotetramine.
Bruun, DA; Crawley, JN; Flannery, BM; Hammock, BD; Lein, PJ; McCoy, MR; Puhger, KR; Silverman, JL,
)
1.81
"Tetramethylenedisulfotetramine (TETS) is a potent convulsant poison for which there is currently no approved antidote. "( Post-exposure administration of diazepam combined with soluble epoxide hydrolase inhibition stops seizures and modulates neuroinflammation in a murine model of acute TETS intoxication.
Austin, AT; Banks, CN; Bruun, DA; Hammock, BD; Inceoglu, B; Lein, PJ; Rogawski, MA; Tancredi, DJ; Vito, ST; Zolkowska, D, 2014
)
1.85
"Tetramethylenedisulfotetramine (TETS) is a potent convulsant GABAA receptor blocker. "( Combined treatment with diazepam and allopregnanolone reverses tetramethylenedisulfotetramine (TETS)-induced calcium dysregulation in cultured neurons and protects TETS-intoxicated mice against lethal seizures.
Austin, AT; Bruun, DA; Cao, Z; Hammock, BD; Hulsizer, S; Inceoglu, B; Lein, PJ; Pessah, IN; Rogawski, MA; Tancredi, DJ; Vito, ST, 2015
)
2.1
"Tetramethylenedisulfotetramine (TETS) is a potent convulsant that is considered a chemical threat agent. "( Tetramethylenedisulfotetramine alters Ca²⁺ dynamics in cultured hippocampal neurons: mitigation by NMDA receptor blockade and GABA(A) receptor-positive modulation.
Cao, Z; Hammock, BD; Lein, PJ; McCoy, M; Pessah, IN; Rogawski, MA, 2012
)
3.26

Effects

ExcerptReferenceRelevance
"Tetramethylenedisulfotetramine has accounted for numerous intentional and unintentional poisonings in China. "( Tetramethylenedisulfotetramine: old agent and new terror.
Barrueto, F; Belson, M; Henderson, AK; Nelson, L; Whitlow, KS, 2005
)
3.21

Dosage Studied

ExcerptRelevanceReference
" The effect of gastric lavage in early stage was especially obvious, 13 cases with convulsions got immediate relief after plasma exchange, the use of large dosage of tranquilizer resulted in better control on convulsion in 4 cases treated with ventilator than that in the others."( [Clinical analysis of 15 cases with tetramethylenedisulfotetramine].
Li, ZJ; Zeng, JY, 2001
)
0.59
" Better effects could be achieved with earlier use of high dosage GABA or Na-DMPS."( The antidotal effects of high-dosage gamma-aminobutyric acid on acute tetramine poisoning as compared with sodium dimercaptopropane sulfonate.
Han, J; Sun, P; Weng, Y, 2007
)
0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (137)

TimeframeStudies, This Drug (%)All Drugs %
pre-199018 (13.14)18.7374
1990's9 (6.57)18.2507
2000's67 (48.91)29.6817
2010's31 (22.63)24.3611
2020's12 (8.76)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.15 (24.57)
Research Supply Index5.02 (2.92)
Research Growth Index5.14 (4.65)
Search Engine Demand Index42.09 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (2.03%)5.53%
Reviews13 (8.78%)6.00%
Case Studies17 (11.49%)4.05%
Observational0 (0.00%)0.25%
Other115 (77.70%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]